BioNTech reported a disappointing quarter, moving from a €259.5 million profit a year ago to a net loss of €305 million. The company posted a per-share loss of €1.25 on revenue of €907.4 million, which was much worse than analysts’ forecasts of a €0.45 loss on €768.3 million in revenue.
The company’s outlook added to the disappointment. Management expects full-year 2026 revenue between €2 billion and €2.3 billion, which is well below the roughly €2.75 billion analysts had predicted. This gap suggests there are ongoing challenges, not just a one-time setback.
Shares dropped about 17% in premarket trading, putting the stock on track for its biggest one-day decline in over four years.
The worsening financial situation comes as the company faces a major leadership change. The co-founders, who are also the chief executive and chief medical officer and started BioNTech in 2008, announced they will leave by the end of the year to start a new biotech company. The supervisory board has begun looking for their replacements. BioNTech plans to give some rights and mRNA technologies to the new company in return for a minority stake, milestone payments, and royalties.
The leadership changes make an already tough situation even harder. Revenue from BioNTech’s main product, developed in partnership, has been declining since the peak of the pandemic. Management expects this decline to continue in both Europe and the U.S. through 2026. Meanwhile, a separate cancer partnership is expected to bring in about the same revenue as last year. In the United States, where mRNA technology — the foundation of BioNTech’s vaccine and cancer immunotherapy pipeline — has come under heightened scrutiny following a change in federal health leadership. The current administration has adopted a skeptical posture toward mRNA-based therapeutics, creating uncertainty around the regulatory pathway for next-generation products.
Prior to Tuesday’s selloff, BioNTech’s U.S.-listed shares had only made small gains in 2026, falling far behind the strong recoveries seen at other vaccine makers.
Featured CoursesRecent news
Spotify Stock Surges 15% on Long-Term Growth Targets and New Premium Features
Spotify shares had their best day in almost seven years, climbing 15% on Thursday. The jump came after the company’s investor day, where Spotify shared long-term revenue and margin goals to give investors a clearer picture of its plans. These specific commitments sparked new interest in the stock after a stretch of weaker performance. Co-CEOs […]
Nebius Stock Jumps 7.8% on $2.6B Bloom Energy Power Deal for AI Data Centers.
Nebius Group shares rose 7.8% in premarket trading after the AI cloud provider announced a $2.6 billion deal with Bloom Energy to supply fuel-cell power for its data centers. This move tackles a major challenge in building AI infrastructure. The deal also highlights the growing power crisis for neocloud operators and explains why Bloom Energy […]
SpaceX IPO Opens to Retail Investors Through Robinhood, Fidelity, and Schwab
SpaceX has announced that some shares will be available through Robinhood, Fidelity, and Charles Schwab. This means everyday traders can access the IPO at the same price and time as big institutional buyers. Here’s what this means for retail investors and why it’s important to pay attention to the details. This approach is different from […]
Trade with fewer limits
Day trade with fewer limits at fast speed. Buy stocks and ETFs at low fees.